Navigation Links
Study Confirms that OrbusNeich's Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
Date:7/11/2011

ate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedical.


'/>"/>
SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... WORCESTER, Mass. and TORONTO ... www.generex.com ) (OTCBB: GNBT) today announced three presentations demonstrating ... developed by its wholly-owned subsidiary, Antigen Express, Inc. ( ... annual meeting of the American Society of Clinical Oncology ... from May 31 through June 4, 2013. ...
(Date:5/22/2013)... , 22. Mai 2013  Grifols, ... in Barcelona , Spanien, ... dass eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer ... mit Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, ... bezeichneten Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, ...
(Date:5/22/2013)... TORONTO , May 22, 2013  Medifocus, Inc. ... John Mon , Chief Operating Officer, will present at ... 30, 2013 in New York City ... presentation is scheduled to begin at 4:00 p.m. EDT and ... webcast, go to:   http://wsw.com/webcast/marcum/mfs.v/   For more ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... acquire Proteolix, Inc., a privately held biopharmaceutical company ... target the proteasome for the treatment of hematological ... carfilzomib, is a proteasome inhibitor currently in multiple ...
... , EXTON, Pa., Oct. 9 Kensey Nash ... release its earnings results for its first quarter ended September ... 22, 2009. , Joe Kaufmann, President and CEO, ... Thursday, October 22, 2009 at 9:00 A.M. Eastern Time. ...
Cached Medicine Technology:Onyx Pharmaceuticals to Acquire Proteolix, Inc. 2Onyx Pharmaceuticals to Acquire Proteolix, Inc. 3Onyx Pharmaceuticals to Acquire Proteolix, Inc. 4Onyx Pharmaceuticals to Acquire Proteolix, Inc. 5Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2
(Date:5/22/2013)... features Toppik and Bosley hair fibers, two hair loss concealer ... balding hair. Hair loss treatments can be a lengthy process. ... this waiting period, one can use these hair loss concealers. ... transplant surgery in general. , Bosley and Toppik Hair ... to eliminate the appearance of balding and thinning hair. It ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Beginning Aug. ... in the Conrad Foundation’s Spirit of Innovation Challenge ... technical plan competition, free and open to students ages ... The Spirit of Innovation Challenge celebrates the life and ... walk on the Moon. The program challenges teens to ...
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 According ... is an autoimmune disorder effecting up to 3 million ... causing damage to the small intestine and mal-absorption of ... such as diarrhea, constipation, weight loss and vitamin deficiency, ... diet. While there are many gluten-free foods that celiac ...
(Date:5/22/2013)... Toronto, May 22 2013 - Research presented today ... reactions in rats similar to those produced by ... results, presented by addiction expert Francesco Leri, Associate ... the University of Guelph, suggest food addiction could ... epidemic. These results were presented at the ...
(Date:5/22/2013)... (HealthDay News) -- Use of the antidepressant Lexapro ... heart condition, a new study finds. ... stress-induced myocardial ischemia." Although people with this condition ... is not receiving adequate blood supply, according to ... Durham, N.C. However, the researchers found that ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 3Health News:Addiction to unhealthy foods could help explain the global obesity epidemic 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 3
... million children under the age of five and 1.7 ... sanitation, an international conference was told Saturday. // , ... utmost importance, and if we have to ensure gender ... problems need immediate attention," said Bindeshwar Pathak, founder, Sulabh ...
... discovery of neural stem cells and their potential for someday ... recent research identified “cancer stem cells,” a small population of ... a malignant brain tumor. Theoretically, if these mother cells can ... itself. On the other hand, if these cells are not ...
... A in a middle school in south China's Guangxi Zhuang ... said Friday//. ,All the students have been identified as ... suffering from symptoms of hepatitis A and 33 others are ... head of the Guangxi centre for disease control and prevention. ...
... Children’s Hospital Boston report a new and efficient strategy, ... that can be transplanted// without the risk of rejection ... system. ,Though done in mice, the work establishes ... of customized embryonic stem cells that are genetically matched ...
... under-report patient safety incidents, particularly those resulting in harm, ... authors suggest that the current system, which relies on ... is to gather accurate information on the extent of ... safety incidents are common in hospitals, and many of ...
... Scientific, technological and medical advances made in the past ... and more effective treatment options/// and better outcomes for ... the article, Shlomo Melmed, M.D., senior vice president for ... Research Institute at Cedars-Sinai, provides an update on medical ...
Cached Medicine News:Health News:Poor Sanitation Causes 3.1 Million Child Deaths In Asia 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 3Health News:Researchers Create Genetically-Matched Embryonic Stem Cells for Transplantation 2Health News:Researchers Create Genetically-Matched Embryonic Stem Cells for Transplantation 3Health News:Hospitals Miss Most Patient Safety Incidents 2Health News:Options Improving for Patients With Acromegaly and Gigantism 2Health News:Options Improving for Patients With Acromegaly and Gigantism 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: